A retrospective analysis of EGFR+ NSCLC patients with brain metastases published in 2017 by Magnuson et al. could demonstrate a survival advantage for the addition of cerebral irradiation to first-/second-generation EGFR inhibitors, which has been a strong argument for the combined approach [38]: in this study, the rate of brain progression was slightly lower for patients treated with TKI and stereotactic (SRT) or whole-brain radiotherapy (WBRT) compared to TKI alone, which also translated to a significant OS benefit in the long run. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.